NCT03764293 2024-02-06
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
Clinical Trials
9 trialsNCT00625378 2022-09-01
STEP
Bayer
Phase 3 Completed
NCT00941863 2016-03-22
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Bayer
Phase 1 Completed
NCT01585870 2015-10-27
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
Bayer
Phase 1 Completed
NCT00259129 2014-11-13
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients
Bayer
Phase 1 Completed
NCT00606125 2014-06-23
Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors
Bayer
Phase 1 Completed
NCT00562913 2013-11-26
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Bayer
Phase 1 Completed
NCT00562523 2013-05-23
Sorafenib/Docetaxel Dose Escalation Trial
Bayer
Phase 1 Completed
NCT00882869 2011-07-13
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Aegera Therapeutics
Phase 1/2 Completed